Nicotinic acetylcholine receptors induce c-Kit ligand/Stem Cell Factor and promote stemness in an ARRB1/β-arrestin-1 dependent manner in NSCLC

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10486-10502

  Perumal, Deepak ^a,b   Pillai, Smitha ^a   Nguyen, Jonathan ^a   Schaal, Courtney ^a   Coppola, Domenico ^a   Chellappan, Srikumar P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

E2F1; Non small cell lung cancer; Rb; Self renewal

Indexed keywords

BETA ARRESTIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINE; NICOTINIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TRANSCRIPTION FACTOR E2F1; BETA ARRESTIN; E2F1 PROTEIN, HUMAN; RETINA S ANTIGEN; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CELL RENEWAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOKING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE;

ADENOCARCINOMA; ARRESTINS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMOKING; STEM CELL FACTOR; TUMOR CELLS, CULTURED;

EID: 84916919339     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2395     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011; 61(2):69-90.
2. Hoffman PC, Mauer AM and Vokes EE. Lung cancer. The Lancet. 2000; 355(9202):479-485.
3. Improgo MR, Tapper AR and Gardner PD. Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer. Biochemical Pharmacology. 2011; 82(8):1015-1021.
4. Dasgupta P and Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle. 2006; 5(20):2324-2328.
5. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL and Corrigall WA. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007; 6(9):746-762.
6. Shin VY, Jin HC, Ng EKO, Yu J, Leung WK, Cho CH and Sung JJY. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and ß-adrenergic receptor signaling pathways. Toxicology and Applied Pharmacology. 2008; 233(2):254-261.
7. Albuquerque EX, Pereira EFR, Alkondon M and Rogers SW. Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function. Physiological Reviews. 2009; 89(1):73-120.
8. Improgo MRD, Scofield MD, Tapper AR and Gardner PD. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: Dual role in nicotine addiction and lung cancer. Progress in Neurobiology. 2010; 92(2):212-226.
9. Levin ED and Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochemical Pharmacology. 2007; 74(8):1182-1191.
10. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C and Gualtieri F. Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. ChemMedChem. 2007; 2(6):746-767.
11. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer. 2009; 9(3):195-205.
12. Melhem-Bertrandt A and Sood AK. New Directions in Reducing Stress Effects on Cancer. Cancer Prevention Research. 2012; 5(2):147-149.
13. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E and Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006; 116(8):2208-2217.
14. Miller WE and Lefkowitz RJ. Expanding roles for ß-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Current Opinion in Cell Biology. 2001; 13(2):139-145.
15. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E and Chellappan SP. ARRB1-Mediated Regulation of E2F Target Genes in Nicotine-Induced Growth of Lung Tumors. Journal of the National Cancer Institute. 2011; 103(4):317-333.
16. Sun A, Bagella L, Tutton S, Romano G and Giordano A. From G0 to S phase: A view of the roles played by the retinoblastoma (Rb) family members in the Rb- E2F pathway. Journal of Cellular Biochemistry. 2007; 102(6):1400-1404.
17. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C and Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of Oncology. 2013; 24(5):1312-1319.
18. Hara MR, Sachs BD, Caron MG and Lefkowitz RJ. Pharmacological blockade of a β2AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. Cell Cycle. 2013; 12(2):219-224.
19. Galli SJ, Zsebo KM and Geissler EN. (1993). The kit Ligand, Stem Cell Factor. In: Frank JD, ed. Advances in Immunology: Academic Press), pp. 1-96.
20. Horie K, Takakura K, Taii S, Narimoto K, Noda Y, Nishikawa S, Nakayama H, Fujita J and Mori T. The expression of c-kit protein during oogenesis and early embryonic development. Biology of Reproduction. 1991; 45(4):547-552.
21. Hassan HT and Zander A. Stem Cell Factor as a Survival and Growth Factor in Human Normal and Malignant Hematopoiesis. Acta Haematologica. 1996; 95(3-4):257-262.
22. Erlandsson A, Larsson J and Forsberg-Nilsson K. Stem cell factor is a chemoattractant and a survival factor for CNS stem cells. Experimental Cell Research. 2004; 301(2):201-210.
23. Dolci S, Williams DE, Ernst MK, Resnick JL, Brannan CI, Lock LF, Lyman SD, Boswell HS and Donovan PJ. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature. 1991; 352(6338):809-811.
24. Mroczko B and Szmitkowski M. Hematopoietic cytokines as tumor markers. Clinical Chemical Laboratory Medicine. 2005; 42(12):1347-1354.
25. Shedden K, Taylor JMG, Enkemann SA, Tsao M-S, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008; 14(8):822-827.
26. Lee E-S, Son D-S, Kim S-H, Lee J, Jo J, Han J, Kim H, Lee HJ, Choi HY, Jung Y, Park M, Lim YS, Kim K, Shim YM, Kim BC, Lee K, et al. Prediction of Recurrence- Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression. Clinical Cancer Research. 2008; 14(22):7397-7404.
27. Lennartsson J and Ronnstrand L. The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer Current Cancer Drug Targets. 2006; 6(1):65-75.
28. Reber L, Da Silva CA and Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. European Journal of Pharmacology. 2006; 533(1-3):327-340.
29. Singh S, Bora-Singhal N, Kroeger J, Laklai H and Chellappan SP. βArrestin-1 and Mcl-1 Modulate Self- Renewal Growth of Cancer Stem-Like Side-Population Cells in Non-Small Cell Lung Cancer. PLoS One. 2013; 8(2):e55982.
30. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S and Chellappan S. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stemlike side-population cells in non-small cell lung cancer. Molecular Cancer. 2012; 11(1):73.
31. Hecht S. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006; 391(6):603-613.
32. Hecht SS. Tobacco Smoke Carcinogens and Lung Cancer. Journal of the National Cancer Institute. 1999; 91(14):1194-1210.
33. Tai M-H, Upham BL, Olson LK, Tsao M-S, Reed DN and Trosko JE. Cigarette smoke components inhibited intercellular communication and differentiation in human pancreatic ductal epithelial cells. International Journal of Cancer. 2007; 120(9):1855-1862.
34. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 1999; 424(1-2):127-142.
35. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D and Chellappan S. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 2009; 4(10):e7524.
36. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E and Chellappan S. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. International Journal of Cancer. 2009; 124(1):36-45.
37. Tammemagi CM, Neslund-Dudas C, SimoffM and Kvale P. Smoking and Lung Cancer Survival-The Role of Comorbidity and Treatment. CHEST Journal. 2004; 125(1):27-37.
38. Videtic GMM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD and Yu EW. Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival. Journal of Clinical Oncology. 2003; 21(8):1544-1549.
39. Fox JL, Rosenzweig KE and OstroffJS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer. 2004; 44(3):287-293.
40. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
41. Perumal D, Singh S, Yoder SJ, Bloom GC and Chellappan SP. A Novel Five Gene Signature Derived from Stem-Like Side Population Cells Predicts Overall and Recurrence-Free Survival in NSCLC. PLoS ONE. 2012; 7(8):e43589.
42. Hassan HT. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leukemia Research. 2009; 33(1):5-10.
43. Chen L, Shen R, Ye Y, Pu X-A, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, et al. Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLoS One. 2007; 2(3):e293.
44. Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM and Takahashi T. Recombinant Human Stem Cell Factor Mediates Chemotaxis of Small-Cell Lung Cancer Cell Lines Aberrantly Expressing the c-kit Protooncogene. Cancer Research. 1993; 53(7):1709-1714.
45. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, Lokshin A and Gorelik E. Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factor-c-kit Autocrine Signaling Loop. Cancer Research. 2010; 70(1):338-346.
46. Höög G, Zarrizi R, von Stedingk K, Jonsson K and Alvarado-Kristensson M. Nuclear localization of ?-tubulin affects E2F transcriptional activity and S-phase progression. The FASEB Journal. 2011; 25(11):3815-3827.
47. Han Z-B, Ren H, Zhao H, Chi Y, Chen K, Zhou B, Liu Y-j, Zhang L, Xu B, Liu B, Yang R and Han Z-C. Hypoxia-inducible factor (HIF)-1a directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis. 2008; 29(10):1853-1861.
48. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, Mitsuya H, Esumi H, Koyama A, Yamamoto M, et al. Overexpression of c-Maf Contributes to T-Cell Lymphoma in Both Mice and Human. Cancer Research. 2006; 66(2):812-819.
49. Jin G, Kim MJ, Jeon H-S, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH and Park JY. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010; 69(3):279-283.
50. Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, Ingolia N and MacPherson D. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. Molecular Cancer Research. 2014; 12(5):654-659.
51. Yang X, Chen M-W, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y and Buttyan R. A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Cancer Research. 2005; 65(12):5263-5271.
52. Smith HA, Cronk RJ, Lang JM and McNeel DG. Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer. Cancer Research. 2011; 71(21):6785-6795.
53. Smith HA and McNeel DG. The SSX Family of Cancer- Testis Antigens as Target Proteins for Tumor Therapy. Clinical and Developmental Immunology. 2010; 2010:18.
54. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. The Journal of Experimental Medicine. 1996; 183(4):1797-1806.